Operator Good afternoon, and welcome to AbCellera's Q3 2024 business update conference call. My name is Tamia, and I will ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2024 and provided a business update. "Regeneron had a strong third quarter marked by 11% ...

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.

Regeneron Pharmaceuticals ( (REGN) ) has released its Q3 earnings. Here is a breakdown of the information Regeneron Pharmaceuticals presented ...

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

Regeneron reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Eylea HD, Dupixent and Libtayo sales.